CN118302170A - 化合物、组合物和方法 - Google Patents

化合物、组合物和方法 Download PDF

Info

Publication number
CN118302170A
CN118302170A CN202280062070.2A CN202280062070A CN118302170A CN 118302170 A CN118302170 A CN 118302170A CN 202280062070 A CN202280062070 A CN 202280062070A CN 118302170 A CN118302170 A CN 118302170A
Authority
CN
China
Prior art keywords
compound
cycloalkyl
heterocyclyl
heteroaryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280062070.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·A·克雷格二世
M·奥西波夫
A·托图姆卡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nico Therapy Co ltd
Original Assignee
Nico Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nico Therapy Co ltd filed Critical Nico Therapy Co ltd
Publication of CN118302170A publication Critical patent/CN118302170A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280062070.2A 2021-09-17 2022-09-16 化合物、组合物和方法 Pending CN118302170A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163245747P 2021-09-17 2021-09-17
US63/245,747 2021-09-17
PCT/US2022/043860 WO2023044043A1 (en) 2021-09-17 2022-09-16 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
CN118302170A true CN118302170A (zh) 2024-07-05

Family

ID=85602045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280062070.2A Pending CN118302170A (zh) 2021-09-17 2022-09-16 化合物、组合物和方法

Country Status (5)

Country Link
US (1) US20240391932A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401739A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024534416A (cg-RX-API-DMAC7.html)
CN (1) CN118302170A (cg-RX-API-DMAC7.html)
WO (1) WO2023044043A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210038877A (ko) * 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
JP2023523418A (ja) * 2020-04-23 2023-06-05 ヤンセン ファーマシューティカ エヌ．ベー． Ｎｌｒｐ３の阻害剤としての三環式化合物

Also Published As

Publication number Publication date
JP2024534416A (ja) 2024-09-20
EP4401739A1 (en) 2024-07-24
US20240391932A1 (en) 2024-11-28
WO2023044043A1 (en) 2023-03-23
EP4401739A4 (en) 2025-07-30

Similar Documents

Publication Publication Date Title
TWI877136B (zh) 化合物、組合物及方法
CN116261456B (zh) 化合物、组合物和方法
AU2021300192A1 (en) Compounds, compositions and methods
WO2008072682A1 (ja) イミダゾ［１，２－ｂ］ピリダジン誘導体
CN117940120A (zh) 化合物、组合物和方法
WO2022109268A1 (en) Compounds, compositions, and methods
CN119233972A (zh) 化合物、组合物和方法
CN118302170A (zh) 化合物、组合物和方法
EP4719392A2 (en) Compounds, compositions, and methods
EP4479054A1 (en) Compounds, compositions, and methods
EP4719393A2 (en) Compounds, compositions, and methods
CN116507608A (zh) 化合物、组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination